Long-term clinical and safety outcomes from a single-site phase 1 study of neural stem cell transplantation for chronic thoracic spinal cord injury
Source: ScienceDirect
Spinal cord injury (SCI) is a devastating condition that results in significant impairment of millions of individuals worldwide.1 Management of SCI primarily focuses on stabilizing the injury, preventing further damage, and rehabilitating the patient to potential functional recovery.2,3 Traditional treatments include surgery and neurological rehabilitation. In recent years, neuromodulation3 and cell-based therapies4 have emerged as promising procedures for SCI. Among the various types of stem cells, fetal-derived neural stem cells (NSCs) have a favorable safety profile due to their established lineage commitment potential and lack of teratoma formation.
